Collaboration of Statisticians: A perspective
*Rajeshwari Sridhara, FDA 

Keywords: clinical trial designs, composite outcomes, FDA Statisticians, collaboration

New drug development is becoming more and more complex with new classification of diseases, use of complex clinical trial designs, composite outcomes, concomitant medications and multi-national studies, just to name a few. Statisticians at FDA, Academia and Industry play an important role and contribute significantly in this complex process. This presentation will include the role of Statisticians at FDA and outline possible areas where Statisticians from different sectors can collaborate to solve complex issues.